Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke
Associated Therapies
-

Development of Minidose Inje Cocktail Method for Simultaneous Evaluating Five Cytochrome P450 Isoforms in Human

First Posted Date
2012-04-04
Last Posted Date
2012-04-04
Lead Sponsor
Inje University
Target Recruit Count
26
Registration Number
NCT01570569

Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia

First Posted Date
2012-03-01
Last Posted Date
2015-09-23
Lead Sponsor
HanAll BioPharma Co., Ltd.
Target Recruit Count
356
Registration Number
NCT01541943
Locations
🇰🇷

Korea University Guro Hospital, Seoul, Korea, Republic of

Losartan to Reverse Sickle Nephropathy

Phase 2
Completed
Conditions
Interventions
First Posted Date
2011-11-24
Last Posted Date
2020-09-29
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
36
Registration Number
NCT01479439
Locations
🇺🇸

Nationwide Children's Hospital, Columbus, Ohio, United States

🇺🇸

University of Illinois at Chicago, Chicago, Illinois, United States

🇺🇸

Texas Children's Hospital, Houston, Texas, United States

and more 6 locations

Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy

Phase 2
Completed
Conditions
Interventions
First Posted Date
2011-10-06
Last Posted Date
2014-07-09
Lead Sponsor
Henning Bundgaard
Target Recruit Count
130
Registration Number
NCT01447654
Locations
🇩🇰

Department of cardiology, Rigshospitalet., Copenhagen, Denmark

The Effect of Losartan in Bicuspid Aortic Valve Patients

Not Applicable
Terminated
Conditions
Interventions
First Posted Date
2011-07-08
Last Posted Date
2017-04-14
Lead Sponsor
University of Michigan
Target Recruit Count
4
Registration Number
NCT01390181
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly

First Posted Date
2011-06-29
Last Posted Date
2018-05-08
Lead Sponsor
The University of Texas Medical Branch, Galveston
Target Recruit Count
6
Registration Number
NCT01384591
Locations
🇺🇸

University of Texas Medical Branch, Galveston, Texas, United States

Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)

First Posted Date
2011-06-13
Last Posted Date
2021-06-03
Lead Sponsor
Relypsa, Inc.
Target Recruit Count
324
Registration Number
NCT01371747
Locations
🇬🇪

Investigator Site 311, Tbilisi, Georgia

🇬🇪

Investigator Site 303, Tbilisi, Georgia

🇬🇪

Investigator Site 308, Tbilisi, Georgia

and more 40 locations

Antihypertensive Effect of Rostafuroxin Compared With Losartan in Hypertensive Patients Bearing Specified Gene Mutations

First Posted Date
2011-03-22
Last Posted Date
2011-03-23
Lead Sponsor
RostaQuo S.p.A.
Target Recruit Count
240
Registration Number
NCT01320397
Locations
🇮🇪

Portiuncula Hospital, Ballinasloe, Galway, Ireland

🇮🇹

Ospedale "Santa Maria", Borgo Val di Taro, Parma, Italy

🇮🇪

James Connolly memorial Hospital, Dublin, Ireland

and more 23 locations
© Copyright 2024. All Rights Reserved by MedPath